Company / SG&A per Share
Fulcrum Therapeutics, Inc. SG&A per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$452.47
FY2025
5-year range
$452.47 / $926.72
FY2021-FY2025
Trend
-23.1%
vs FY2024
Sector context
#3 of 210
Health Care
What the data says
Among 210 Health Care companies, Fulcrum Therapeutics, Inc. is in the bottom 1% for sg&a per share. SG&A per Share has declined for 3 consecutive years, from $926.72 in FY2022 to $452.47 in FY2025.
Based on SEC 10-K filings.
452.47 in FY2025 with a 5-year CAGR of -11.7%. Ranks 3rd among 210 companies in Health Care.
Improved from $679.63 to $452.47 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- -21.3%
- 5-Year CAGR
- -11.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 210This company $452.47 Sector average $40.75
▼
+1010.3% above sector average
Key checks
Key Insights
- Fulcrum Therapeutics, Inc.'s sg&a per share has declined for 3 consecutive years.
- In FY2025, sg&a per share decreased 23.1% year-over-year.
- Ranks #3 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $452.47 | -23.1% |
| FY2024 | $588.02 | -13.5% |
| FY2023 | $679.63 | -26.7% |
| FY2022 | $926.72 | +7.4% |
| FY2021 | $862.98 | +2.3% |
| FY2020 | $843.73 | -29.1% |
| FY2019 | $1190.02 | -82.0% |
| FY2018 | $6614.16 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026